Compare HFBL & SKYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HFBL | SKYE |
|---|---|---|
| Founded | 1924 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 41.6M | 44.9M |
| IPO Year | N/A | N/A |
| Metric | HFBL | SKYE |
|---|---|---|
| Price | $17.93 | $1.00 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $14.75 |
| AVG Volume (30 Days) | 5.4K | ★ 609.2K |
| Earning Date | 01-27-2026 | 11-10-2025 |
| Dividend Yield | ★ 3.01% | N/A |
| EPS Growth | ★ 35.20 | N/A |
| EPS | ★ 1.47 | N/A |
| Revenue | ★ $21,720,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $12.21 | ★ N/A |
| Revenue Growth | ★ 10.10 | N/A |
| 52 Week Low | $12.31 | $0.68 |
| 52 Week High | $19.20 | $5.75 |
| Indicator | HFBL | SKYE |
|---|---|---|
| Relative Strength Index (RSI) | 58.32 | 49.38 |
| Support Level | $17.40 | $0.68 |
| Resistance Level | $17.90 | $1.10 |
| Average True Range (ATR) | 0.47 | 0.10 |
| MACD | -0.02 | 0.03 |
| Stochastic Oscillator | 86.83 | 70.68 |
Home Federal Bancorp Inc of louisiana operates as a bank holding company. It is a federally chartered stock savings bank, which provides financial services to individuals, corporate entities, and other organizations. Its core activities consist of attracting deposits from the general public and using those funds to originate loans to the residential, commercial and multi-family segments. The company also invests securities held-to-maturity and securities available for sale.
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.